Skip to content
GHIAA Logo Small
Envelope Linkedin-in Twitter
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
    • Newsletter
  • Contact
  • search
Menu
  • Home
  • Our Work
    • GHIAA
    • MAPGuide
    • Vaccine Manufacturing
  • About
    • About GHIAA
    • Team
  • News
  • Resources
    • Useful Links
    • Newsletter
  • Contact
  • search
 
search

CEPI – CureVac, Framework Partnering Agreement

  • Post author:GHIAA Editor
  • Post published:June 30, 2021
  • Post category:

Continue ReadingCEPI – CureVac, Framework Partnering Agreement

European Commission – CureVac, COVID-19 Vaccine Advance Purchase Agreement

  • Post author:GHIAA Admin
  • Post published:January 25, 2021
  • Post category:

Continue ReadingEuropean Commission – CureVac, COVID-19 Vaccine Advance Purchase Agreement

EDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingEDCTP2 Policy on Clinical Trials Registration, Publication and Data Sharing

IMI 2 Model Grant Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingIMI 2 Model Grant Agreement

Funder Development Partnering Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingFunder Development Partnering Agreement

Funder Development Partnering Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingFunder Development Partnering Agreement

Funder Development Partnering Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingFunder Development Partnering Agreement

MPP – AbbVie, HIV Antiretroviral Sublicense Agreement

  • Post author:GHIAA Editor
  • Post published:May 22, 2020
  • Post category:

Continue ReadingMPP – AbbVie, HIV Antiretroviral Sublicense Agreement

IMI 2 Model Grant Agreement

  • Post author:GHIAA Editor
  • Post published:May 21, 2020
  • Post category:

Continue ReadingIMI 2 Model Grant Agreement
  • Go to the previous page
  • 1
  • 2
  • 3
  • Go to the next page

Recent Posts

  • MAPGuide Glossary (DRAFT)
  • Key Terms of Alliance Agreements

Recent Comments

    Archives

    • May 2020

    Categories

    • Resource & Analysis

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    Get In Touch

    comms@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    Our Work
    MAPGuide
    About GHIAA
    Team
    News
    Useful Links
    COVID19

    Contact Us

    Get In Touch

    info@ghiaa.org

    Tel: 919-419-0300
    919-906-4818
    Fax: 919-419-8833

    Attn: Executive Director
    GHIAA
    PO Box 14713
    Research Triangle Park, NC 27709, USA

    Browse

    GHIAA
    MAPGuide
    About GHIAA
    Team
    News
    Links
    COVID19

     

    Twitter Linkedin-in
    comms@ghiaa.org

    Privacy Policy

    • Privacy Policy
    • Join
    Menu
    • Privacy Policy
    • Join

    © 2022 Global Healthcare Innovation Alliance Accelerator. All Rights Reserved

    Sign Up to Our Newsletter

    Receive updates about GHIAA’s latest tools, resources and news.

    I consent to receiving email updates from GHIAA and have read and agree to the Privacy Policy and Terms of Service..

    Agreement Type

    • Any Agreement Types
    • License
    • Manufacturing
    • Other
    • Research & Development
    • Supply/Purchase
    • Technology Transfer

    Select Partner Type

    • Any Partner types
    • Academic institution
    • Funder
    • Government
    • Industry
    • Multilateral organization
    • Product development partnership

    Select Development Stage

    • Any Develoment stages
    • Discovery/Concept
    • Preclinical
    • Early clinical (through Phase 2)
    • Late clinical (Phase 3)
    • Commercialization
    • Field Testing

    Select Technology

    • Any Technologies
    • Device
    • Diagnostic
    • Drug
    • Vaccine

    Select Issue or Sub-issues

    • Equitable Access
      • All Equitable Access
      • Donation
      • Ensuring continuity
      • Access plans & principles
      • Preparedness & response
      • Affordable pricing
      • Territory access commitments
    • Business model
      • All Business model
      • Benefit sharing
      • Regulatory strategy
      • Governance
      • Payment Structures
      • Product supply
    • Protecting & sharing information
      • All Protecting & sharing information
      • Confidentiality
      • Information sharing
      • Publication of Results
      • Technology transfer
    • Intellectual Property
      • All Intellectual Property
      • License Grants
      • Ownership of IP
      • Protection of IP
    • Liability
      • All Liability
      • Indemnification & liability
      • Insurance
      • Representations & Warranties
    • Term & termination
      • All Term & termination
      • Effects of termination
      • Term of agreement
      • Termination & withdrawal